Project Details
| Status | Active |
|---|---|
| Effective start/end date | 3/11/24 → 3/11/27 |
Funding
- Takeda Pharmaceuticals U.S.A., Inc. (Prot #Vedolizumab-4052)
Prot #Vedolizumab-4052: Re-define the IBD disease burden status
- Dulai, Parambir Singh (PD/PI)
Project: Research project